Search

AstraZeneca PLC

Closed

SectorHealthcare

169.25 -1.17

Overview

Share price change

24h

Current

Min

169.03

Max

173.33

Key metrics

By Trading Economics

Income

-1.4B

2.5B

Sales

-94M

15B

P/E

Sector Avg

25.587

64.641

EPS

2.63

Profit margin

16.296

Employees

96,100

EBITDA

-694M

5B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+25.77% upside

Dividends

By Acuity

Next Earnings

30 Oct 2026

Next Dividend date

8 Sept 2026

Next Ex Dividend date

6 Aug 2026

Market Stats

By TradingEconomics

Market Cap

558M

263B

Previous open

170.42

Previous close

169.25

News Sentiment

By Acuity

32%

68%

101 / 340 Healthcare

AstraZeneca PLC Chart

Past performance is not a reliable indicator of future results.

Related News

30 Jul 2026, 23:56 UTC

News

Old Dominion Freight Line shares lower in after-market hours after UBS raised its price target to $228 while maintaining a Neutral rating.

30 Jul 2026, 23:56 UTC

News

DICK'S Sporting Goods Inc. sees gains in after-market trading, supported by solid fundamentals and recognition as a value stock despite mixed performance momentum.

30 Jul 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

30 Jul 2026, 23:56 UTC

News

Check Point Software Technologies reported earnings of $2.55 per share, surpassing expectations of $2.45. Shares are little changed in after-market trading.

30 Jul 2026, 23:52 UTC

News
Social Media

Amazon.com Inc shares rose in after-hours trading following strong second-quarter results, with net sales of $200.6 billion surpassing analyst expectations.

30 Jul 2026, 23:51 UTC

News

Kimberly-Clark announced a $10 million commitment for recovery efforts in Wisconsin's Fox Valley, moving higher in after-market hours amid broader market gains.

30 Jul 2026, 23:51 UTC

News

Boston Scientific shares are higher in after-market trading following UBS's Buy rating and a price target adjustment to $67 amid Penumbra's results.

30 Jul 2026, 23:51 UTC

News

Castle Biosciences reported second-quarter revenues of $103.5 million, exceeding estimates. Shares are sharply higher in after-market trading following the earnings and guidance update.

30 Jul 2026, 23:51 UTC

News

Hercules Capital reported second-quarter earnings of $0.50 per share, exceeding estimates. Shares are higher in after-market trading following the strong results.

30 Jul 2026, 23:51 UTC

Correlated Moves
News

EMCOR Group Inc. reported record second-quarter results, with revenue of $5.15 billion and EPS of $9.06, raising full-year guidance. Shares are higher in after-market hours.

30 Jul 2026, 23:51 UTC

Social Media
Correlated Moves
News

Lam Research Corp shares rose in after-market hours following strong second-quarter results, with adjusted EPS of $1.82 and optimistic third-quarter revenue guidance of $8.1 billion.

30 Jul 2026, 23:51 UTC

News
Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

30 Jul 2026, 23:51 UTC

News
Social Media

Roblox Corp shares fell in after-hours trading following a narrower net loss of $183 million but disappointing revenue and guidance for third-quarter bookings.

30 Jul 2026, 23:51 UTC

News
Social Media

Replimune Group shares are advancing in after-market trading following a favorable FDA advisory vote on its melanoma treatment RP1, despite earlier declines during the session.

30 Jul 2026, 23:51 UTC

News
Event
Social Media

Apple Inc reported fiscal Q3 revenue of $109.4 billion, but shares fell in after-hours trading due to weaker-than-expected guidance and missed services revenue.

30 Jul 2026, 23:46 UTC

News

TFS Financial Corp reported third-quarter EPS of $0.11, surpassing estimates. Shares are higher in after-market trading following strong earnings and revenue results.

30 Jul 2026, 23:46 UTC

News

Eastman Chemical Co reported second-quarter net earnings of $183 million, up from $140 million last year, with shares trading roughly flat in after-market hours.

30 Jul 2026, 23:46 UTC

Correlated Moves
News

UBS raised its price target on Xylem Inc. to $135, as shares traded higher in after-market hours following a dip earlier in the session.

30 Jul 2026, 23:46 UTC

Social Media
News

Yum Brands reported a cyclospora outbreak linked to Taco Bell affecting sales. Shares are trading higher in after-market hours, continuing recent upward momentum.

30 Jul 2026, 23:46 UTC

News

Shares of Netflix are lower in after-market trading following Anne Sweeney's resignation from the board, confirmed not to be due to any disagreement.

30 Jul 2026, 23:41 UTC

News

CareDx Inc reported second-quarter revenue of $132 million, exceeding estimates. Following strong results and raised guidance, shares are higher in after-market trading.

30 Jul 2026, 23:41 UTC

Social Media
Event
News

Karyopharm Therapeutics shares fell sharply after its Phase 3 trial for selinexor failed to meet key endpoints, leading to a shift in focus away from endometrial cancer.

30 Jul 2026, 23:41 UTC

Social Media
Correlated Moves
News

MicroStrategy reported a second-quarter loss of $8.62 billion, significantly missing expectations. Shares are trading higher in after-market hours amid broader market gains.

30 Jul 2026, 23:41 UTC

News
Social Media

Illumina Inc shares declined in after-market trading despite strong second-quarter results and raised full-year EPS guidance, reflecting concerns over falling net income.

30 Jul 2026, 23:41 UTC

Social Media
News

Stryker Corp shares fell in after-market trading despite reporting adjusted EPS of $3.69 and raising full-year guidance to $14.95 to $15.10.

30 Jul 2026, 23:41 UTC

News

Cerus Corporation shares declined in after-market hours following a revenue miss and lowered full-year guidance, despite second-quarter earnings matching estimates.

30 Jul 2026, 23:41 UTC

News

Cognizant Technology Solutions shares are lower in after-market trading despite stable revenue and increased profit guidance in its recent second-quarter update.

30 Jul 2026, 23:41 UTC

Correlated Moves
News
Social Media

Micron Technology's after-market hours trading rises significantly, driven by a broader market rally and a $153 billion increase in market capitalization.

30 Jul 2026, 23:41 UTC

News

Bloom Energy Corp shares are higher in after-market hours, driven by strong performance in the Heavy Electrical Equipment sector and significant revenue growth.

30 Jul 2026, 23:41 UTC

News

PTC Inc. gained in after-market hours, driven by strong quarterly results and raised revenue guidance, reaching a high of 2.82% since Thursday's close.

Peer Comparison

Price change

AstraZeneca PLC Forecast

Price Target

By TipRanks

25.77% upside

12 Months Forecast

Average 217.962 USD  25.77%

High 271.752 USD

Low 154.71 USD

Based on 14 Wall Street analysts offering 12 month price targets forAstraZeneca PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

12

Buy

1

Hold

1

Sell

Sentiment

By Acuity

101 / 340 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
help-icon Live chat